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Transformation	of	epithelial	cells	is	associated	with	loss	of	cell	polarity,	which	includes	alterations	in	cell	mor-
phology	as	well	as	changes	in	the	complement	of	plasma	membrane	proteins.	Rab	proteins	regulate	polarized	
trafficking	to	the	cell	membrane	and	therefore	represent	potential	regulators	of	this	neoplastic	transition.	
Here	we	have	demonstrated	a	tumor	suppressor	function	for	Rab25	in	intestinal	neoplasia	in	both	mice	and	
humans.	Human	colorectal	adenocarcinomas	exhibited	reductions	in	Rab25	expression	independent	of	stage,	
with	lower	Rab25	expression	levels	correlating	with	substantially	shorter	patient	survival.	In	wild-type	mice,	
Rab25	was	strongly	expressed	in	cells	luminal	to	the	proliferating	cells	of	intestinal	crypts.	While	Rab25-defi-
cient	mice	did	not	exhibit	gross	pathology,	ApcMin/+	mice	crossed	onto	a	Rab25-deficient	background	showed	
a	4-fold	increase	in	intestinal	polyps	and	a	2-fold	increase	in	colonic	tumors	compared	with	parental	ApcMin/+	
mice.	Rab25-deficient	mice	had	decreased	β1	integrin	staining	in	the	lateral	membranes	of	villus	cells,	and	this	
pattern	was	accentuated	in	Rab25-deficient	mice	crossed	onto	the	ApcMin/+	background.	Additionally,	Smad3+/–	
mice	crossed	onto	a	Rab25-deficient	background	demonstrated	a	marked	increase	in	colonic	tumor	formation.	
Taken	together,	these	results	suggest	that	Rab25	may	function	as	a	tumor	suppressor	in	intestinal	epithelial	
cells	through	regulation	of	protein	trafficking	to	the	cell	surface.
Introduction
Alterations in membrane-trafficking patterns can radically affect 
the maintenance of polarity in differentiated epithelial cells, 
and a loss of polarity is thought to play a critical role in the early 
pathogenesis of neoplasia (1, 2). Rab small GTPases are involved 
in the full gamut of vesicle-trafficking pathways within cells (3, 4). 
In particular, the Rab11 family members, consisting of Rab11a, 
Rab11b, and Rab25, regulate various aspects of membrane recy-
cling and trafficking to the plasma membrane (5, 6). Rab25 is 
enriched in epithelial cells (5). Prominent expression of Rab25 has 
been observed throughout the gastrointestinal mucosa, with the 
highest expression seen in ileum and colon. High levels of expres-
sion are also present in the lung and kidney, with a very minor 
and variable level of expression in splenic tissue. No expression 
of Rab25 has been seen in the brain, heart, liver, skeletal muscle, 
or the gastric wall (5). Recent investigations have suggested that 
Rab25 expression can alter breast and ovarian tumor cell-line 
behavior. Cheng et al. (7) noted that MCF-7 breast carcinoma cells 
exhibited more aggressive properties following overexpression of 
Rab25. In contrast, Rao and colleagues (8) have suggested that loss 
of Rab25 in breast cancer cell lines lacking estrogen and proges-
terone receptors leads to more aggressive behavior. It seems likely 
that some of these divergent findings may result from regulation 
of pathways dictating the trafficking of specific cargoes. Recent 
studies have indicated that, in an ovarian cancer cell line, Rab25 
associates with and regulates the trafficking of α5β1 integrin and 
that this can alter tumor cell invasion in vitro (9).
Current models for colorectal adenocarcinoma implicate serial 
genetic alterations within the colonic epithelium as the basis of 
cancer formation. Based on its genetic origin, colon cancer can be 
divided into 2 classes, polyposis colon cancer and nonpolyposis 
colon cancer. Genes whose mutations are responsible for colon car-
cinogenesis have been discovered through molecular genetic studies 
of hereditary cancer predisposition syndromes such as familial ade-
nomatous polyposis (FAP) and hereditary nonpolyposis colorectal 
cancer (HNPCC) (10, 11). Individuals with FAP develop numerous 
benign colorectal polyps due to a germline mutation in the adeno-
matous polyposis coli (APC) gene, which was identified on chromo-
some 5q as one of the genes commonly deleted in FAP kindreds (12, 
13). The first mouse mutant in the Apc gene (the mouse homolog 
of human APC on mouse chromosome 18) was identified from a 
colony of randomly mutagenized mice (14). This mutant, multiple 
intestinal neoplasia (Min) carried a truncation mutation at codon 
850 of the Apc gene; hence the designation of ApcMin (15). All Apc 
mutant mice develop adenomatous polyps in the small intestine 
and with lower frequency also in the colon, but tumors rarely prog-
ress to adenocarcinoma. If additional mutations are introduced 
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into these mice, however, these additional genetic events can lead to 
development of more advanced tumors (16, 17). HNPCC is caused 
by mutations in the genes that encode the enzymatic machinery 
for mismatch repair (18). One locus that is mutated in HNPCC 
encodes the type II receptor for TGF-β (19). A commonly mutated 
pathway in colon cancer exhibiting microsatellite instability is the 
TGF-β pathway. The SMAD proteins are downstream effectors 
of the TGF-β signaling pathway. As a progressive model of colon 
cancer, all of the Smad3–/– mice on the 129/Sv background develop 
proximal and/or distal colonic tumors by 6 months of age (20).
We have sought to determine the effects of loss of Rab25, an epi-
thelial-specific small GTPase, on the evolution of colonic neopla-
sia. We have observed that Rab25 expression is significantly lower 
in human colon cancers independent of stage and lower Rab25 
expression predicts poorer survival. In mice, targeted disruption 
of Rab25 expression promotes intestinal neoplasia in 2 different 
pathway models of either intestinal polyposis or colon carcinogen-
esis. We also have shown that loss of Rab25 in the intestine leads to 
a reduction in basolateral presentation of β1 integrin in intestinal 
villi and correlates with the promotion of polyp formation. Taken 
together, all of this work supports a role of Rab25 as a tumor sup-
pressor in intestinal mucosae.
Results
Rab25 gene expression in human colon cancer. Given the findings in 
breast cancer specimens, which suggested that Rab25 levels were 
altered in breast cancer, we interrogated an established database 
of gene-expression profiles for human colon cancers (21). Gene 
expression was assessed for Rab25 using the Affymetrix 218186 
probe set. Expression of Rab25 was significantly decreased in 
colon adenocarcinomas compared with normal colon (P < 0.03) 
independent of Duke’s stage. Rab25 expression was also reduced 
in LN metastases as well as in liver and lung metastases (Figure 
1A). Moreover, we also compared overall survival in colon cancer 
Figure 1
Rab25 gene expression and human colon cancer. (A) Rab25 expression in a cohort of colon cancer patients and controls with extensive gene 
microarray expression profiling. Gene expression was assessed for Rab25 using the Affymetrix 218186 probe set (numbers in bars indicate 
patient numbers). Expression of Rab25 was significantly decreased in colon adenocarcinomas compared with normal colon (NL) (*P < 0.03) 
independent of Duke’s stage. Rab25 expression was also reduced in LN metastases as well as in liver (LiM) and lung (LuM) metastases. All 
values are shown as mean ± SEM. (B) Comparison of overall survival in colon cancer patient data for gene Rab25. Kaplan-Meier analysis was 
performed comparing patients with Rab25 expression above the median (high Rab25 expression) or with Rab25 expression below the median 
(low Rab25 expression). Lower expression of Rab25 correlated with significantly lower survival (P < 0.035). (C) Normalized expression for 
Rab25 in 6 colon adenoma and 55 colon adenocarcinoma samples from Vanderbilt analyzed by microarray. Rab25 expression was significantly 
decreased in the adenocarcinoma group compared with the adenomas (*P = 0.02). All values are shown as mean ± SEM. (D) Normalized 
expression data for Rab25 across adenomas and individual AJCC stages (I–IV). Rab25 transcript expression was significantly lower in stage I 
and stage IV tumor specimens (*P < 0.001 and **P = 0.02, respectively) compared with specimens from patients with adenomas. All values are 
shown as mean ± SEM.
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patients according to expression of Rab25. Kaplan-Meier analysis 
was performed comparing survival in patients with Rab25 expres-
sion above the median (low risk) to those with Rab25 expression 
below the median (high risk). Lower expression of Rab25 corre-
lated with significantly shorter survival (P < 0.035) (Figure 1B). 
These results suggested that Rab25 might act as a tumor sup-
pressor in the colon.
To determine whether Rab25 was differentially expressed in an 
independent cohort of colorectal cancer patients, we interrogated 
Affymetrix gene microarray results for expression of Rab25 (probe 
218186) in patients with adenomas (n = 6) and adenocarcinomas 
(n = 55) from Vanderbilt Medical Center (22). The demographics for 
this group are listed in Supplemental Table 1 (supplemental mate-
rial available online with this article; doi:10.1172/JCI40728DS1). 
We found that Rab25 expression was significantly lower in the 
adenocarcinoma group compared with adenomas (Figure 1C; 
P = 0.02). Additionally, we evaluated adenomas and individual stage 
groups and found significant differences in the stage I and stage IV 
patients when compared with adenomas (Figure 1D; P < 0.001 and 
P = 0.02) and a trend toward lower expression for the stage II and III 
patients (Figure 1D; P = 0.07 and P = 0.06, respectively).
To verify the results in gene microarray studies, we examined 
Rab25 expression levels in RNA from 4 normal colon samples 
from patients with diverticulitis compared with 10 colon adeno-
carcinoma patient samples by quantitative RT-PCR analysis. The 
colon adenocarcinoma samples spanned the range of stages, with 
3 stage I, 4 stage II, 2 stage III, and 1 stage IV tumor. To quan-
titate differences, we calculated the efficiency-adjusted Ct values 
for each normal and tumor sample (see Methods). We observed 
significantly lower expression of Rab25 in colon tumor samples 
compared with normal colon samples (Figure 2; P = 0.01). Taken 
together, these data confirmed that Rab25 expression was signifi-
cantly decreased in adenocarcinomas and supported a potential 
tumor-suppressive role for Rab25 in colorectal cancer.
Construction and characteristics of Rab25-knockout mouse. To address 
directly the effects of reduced Rab25 expression on colonic neo-
plasia, we constructed a mouse with targeted disruption of the 
Rab25 gene (Figure 3). Rab25-deficient mice were born in normal 
Mendelian ratios and did not show any significant abnormalities 
up to 4 months of age. Mice were bred through 12 generations of 
crossing to either C57BL/6 or 129/J strain backgrounds without 
any alterations in gross phenotype. Rab25-deficient mice did not 
show any detectable levels of Rab25 mRNA, and in addition, there 
was a complete absence of detectable Rab25 protein (Figure 3D). 
Interestingly, we observed that heterozygous mice showed inter-
mediate reductions in Rab25 protein expression, suggesting hap-
loinsufficiency (Figure 3D). C57BL/6 background mice showed 
no significant anatomical or pathological abnormalities up to 
1 year of age. For Rab25-deficient mice on the 129/J background 
only, after 10 months of age, we observed the development of vagi-
nal cancer in virgin females and distal esophageal stricture due to 
squamous cell hyperplasia in both males and females (K.T. Nam, 
unpublished observations).
Rab25 is an epithelial-specific small GTPase (5). Therefore, as 
a final means to establish the efficacy of the Rab25 knockout, we 
compared the staining for Rab25 in intestine in wild-type versus 
Rab25-deficient mice. Figure 3E demonstrates that Rab25 was 
most strongly expressed in cells on the luminal side of the prolif-
erative zone in intestinal crypts. Rab25 staining localized to the 
perinuclear region in a pattern similar to that observed previously 
in Barrett epithelium (23). No staining for Rab25 was observed in 
the intestines of Rab25-knockout mice (Figure 3E).
The effects of Rab25 deficiency associated with tumor initiation in the 
ApcMin/+ mice. ApcMin/+ mice, which are heterozygous for mutant Apc, 
develop multiple polyps in the small bowel and a smaller number 
of polyps in the colon (24). To assess the role of Rab25 in regulating 
tumorigenesis, we examined polyp formation in ApcMin/+ mice bred 
onto a background of Rab25+/+, Rab25+/–, or Rab25–/–. Figure 4 dem-
onstrates that ApcMin/+;Rab25–/– mice showed an increase in tumor 
formation throughout the intestines. We observed a significant 
4-fold increase in tumor number (Figure 4, B and C, and Supple-
mental Table 2). Interestingly, ApcMin/+;Rab25+/– mice also showed a 
significant increase in tumor number that was intermediate between 
wild-type and Rab25-deficient mice (Figure 4B and Supplemental 
Table 2). These studies indicated that Rab25 loss promoted adenoma 
formation and that the effects correlated with Rab25 dosage.
We also examined the presence of colonic tumors in ApcMin/+ mice 
on the Rab25-deficient or heterozygous backgrounds. Figure 5  
demonstrates that ApcMin/+;Rab25–/– mice showed a significant 
2-fold increase in colonic polyp number as well as a significant 
increase in polyp size (Figure 5B and Supplemental Table 2). We 
also observed that polyps were distributed more widely in the colon 
in ApcMin/+;Rab25–/– (Figure 5B). The results indicate that Rab25 loss 
is associated with increased tumor formation in ApcMin/+ mice.
Microscopic examination of the ApcMin/+ mouse tumors in both 
the intestine and colon showed that the lesions were tubular adeno-
mas, as previously noted in ApcMin/+ mice (Figures 4 and 5). We did 
not observe any increase in invasive character in the adenomas in 
Figure 2
Rab25 expression is lower in colon cancers compared with normal 
colonic mucosa. 14 patient samples (4 normal colon samples and 10 
colon adenocarcinomas) were examined by quantitative RT-PCR anal-
ysis. The 1/Ct adjusted Rab25 expression values were determined for 
all samples. A significant reduction of Rab25 expression was observed 
when normal samples were compared with tumor samples (*P = 0.01; 
Mann-Whitney U test). All values are shown as mean ± SEM.
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ApcMin/+;Rab25–/– mice. Since adenoma formation in ApcMin/+ mice has 
been associated with loss of heterozygosity at the wild-type locus 
(25, 26), we have evaluated Apc alleles in microdissected adenomas. 
We observed no difference in the frequency of loss of heterozygosity 
in ApcMin/+;Rab25+/+ mice compared with ApcMin/+;Rab25–/– mice (data 
not shown). These results indicate that loss of Rab25 does not alter 
induction of the loss of heterozygosity at the Apc locus.
We also examined the distribution of Rab25 in ApcMin/+ mice. 
Figure 6 demonstrates that ApcMin/+ mice with a wild-type Rab25 
background showed decreased Rab25 immunostaining in the 
cells at the transition from crypt to villus (Figure 3E vs. Figure 
6, A and E). Interestingly, we also observed ectopic expression of 
Rab25 in villus cells adjacent to intestinal polyps (Figure 6, C and 
G). Also, we observed no staining for Rab25 in ApcMin/+ mouse 
intestinal adenomas and polyps (Figure 6, C and F). As expected, 
no Rab25 staining was found in ApcMin/+ mice on a Rab25-defi-
cient background (Figure 6, D and H).
Rab25 deficiency and β1 integrin localization in intestinal cells. Previ-
ous studies have linked Rab25 to the trafficking of β1 integrin (9). 
Therefore, we examined the distribution of β1 integrin in ApcMin/+ 
and Rab25-deficient mice (Figure 7). In wild-type mice, β1 integ-
rin staining was prominently observed at the lateral membrane 
in villus cells, with less staining in crypt cells (Figure 7A). In con-
trast, villus cells in Rab25-deficient mice had diminished lateral 
staining with more prominent intracellular staining for β1 inte-
grin (Figure 7B). In ApcMin/+ mice, we noted a similar decrease in 
β1 integrin staining in the lateral membranes of villus cells not 
immediately associated with adenoma formation as well as in the 
adenomas themselves (Figure 7, C and E). In ApcMin/+;Rab25–/– mice, 
we observed essentially complete loss of lateral β1 integrin staining, 
and staining was only detected intracellularly (Figure 7D). These 
results suggested that loss of Rab25 affected β1 integrin localiza-
tion in intestinal cells.
The effects of Rab25 deficiency associated with tumor invasion in Smad3+/– 
mice. Given the striking increase in tumorigenesis observed in ApcMin/+ 
mice on the Rab25-deficient background, we sought to evalu-
ate the effects of Rab25 loss in a second model associated with 
colon tumor invasion. Loss of Smad3 in mice is associated with 
development of colon tumors in the proximal colon (20). While 
Smad3–/– mice develop invasive proximal colon tumors, Smad3 
heterozygotes show little if any overt pathology (20). We therefore 
examined the effects of Rab25 deficiency on the colonic mucosa of 
Figure 3
Construction of Rab25-knockout mouse. (A) Schematic 
of the targeting construct for disruption of the Rab25 
gene with insertion of the neomycin sequence into exon II 
of the Rab25 gene. The NEO cassette contained ter-
mination codons in all 3 frames. (B) Southern blot of 
EcoRV digests of DNA from heterozygote (+/–), homo-
zygote wild-type (+/+), and 2 Rab25-knockout mice 
(–/–) probed with sequence from exon V. (C) 3 oligonu-
cleotide PCR-based screening assays showed discrimi-
nation of Rab25-knockout mice from heterozygotes and 
wild-type littermate mice. (D) Western blot of extracts of 
protein (50 mg) from the gastric mucosa of littermate 
mice probed with rabbit anti-mouse Rab25 showing 
reduction of Rab25 expression in heterozygotes and 
complete absence of detectable Rab25 in Rab25-
knockout mice. The distribution of molecular mass 
standards is indicated at left (kDa). The lane images 
shown are from noncontiguous lanes of the same gel 
and Western blot. (E) Immunohistochemical localization 
of Rab25 in the intestinal mucosa of wild-type mice (+/+) 
using either immunohistochemistry (left 2 panels) or 
immunofluorescence (third panel; green is Rab25 and 
blue is DAPI). The cells in the transition zone between 
the crypt and the villus stained most strongly for Rab25. 
In Rab25-deficient mice (–/–, far right), no Rab25 stain-
ing was observed. Scale bars: 50 μm.
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Smad3+/– mice. While Smad3+/– mice on a Rab25+/+ background did 
not show any adenomas (Figure 8, A and B), the Smad3+/–;Rab25–/– 
mice showed large invasive lesions in 80% of animals (Table 1). 
Tumors were identified in both the proximal colonic mucosa and 
in the rectum. By microscopic analysis, in Smad3+/–;Rab25–/– mice, a 
spectrum of tumors was documented that ranged from aberrant or 
dysplastic crypts, hyperplastic lesions, and adenomatous polyps to 
cancerous lesions with progressive degrees of atypia and invasion 
(Table 1). The colonic epithelial tumors often extended into and 
through the submucosa with neoplastic glands penetrating the 
muscle wall (Figure 8, C and E, and Table 1). In a typical example 
of a more aggressive proximal tumor, the glandular atypia resulted 
in numerous mucin-filled cysts (Figure 8, C, D, F, and G). In 
Rab25–/– mice on the 129 background, independent of Smad3, we 
also observed neoplastic vaginal squamous epithelial cells invad-
ing the muscle layer (Figure 8H). All of these results support a role 
for Rab25 loss in the early promotion of colonic neoplasia.
Discussion
Rab small GTPases have been the focus of considerable investiga-
tion over the past decade as critical regulators of intracellular vesi-
cle trafficking. It seems intuitive that membrane trafficking is likely 
involved in many aspects of cell biology relevant to carcinogenesis, 
including loss of polarity, cell invasion, and cell metastasis. How-
ever, few studies have directly addressed the role of Rab proteins 
in epithelial neoplasia. Nevertheless, investigations over the past 
several years have increasingly pointed to roles for Rab proteins and 
their effectors in the regulation of aspects of the establishment and 
maintenance of polarity (27). The loss of polarity in epithelial cells 
represents a critical early event in the pathway toward neoplastic 
transformation (28). Rab11a, Rab11b, and Rab25 share a number 
of effectors (6, 29). While initial studies had suggested that overex-
pression of Rab25 potently inhibited trafficking through the apical 
recycling system (30), it remains unclear whether these results were 
a direct effect or the result of competition for regulators shared 
with Rab11a, an established promoter of recycling system traf-
ficking. Indeed, this competition between Rab11a and Rab25 for 
effectors could be physiologically relevant and regulate the balance 
between various membrane-trafficking pathways. Imbalances in 
trafficking could lead to alterations in membrane components that 
would affect critical aspects of membrane polarity.
Previous studies have noted an increase in Rab25 expression in 
some ovarian and breast cancers (7). However, other studies have 
suggested that in estrogen receptor–negative breast cancers, loss of 
Rab25 actually promotes a more aggressive phenotype (8). We have 
examined induction of breast cancer and metastases in MMTV-
Figure 4
Rab25 deficiency promotes intestinal adenoma formation in ApcMin/+ mice. (A) Gross appearance of small intestine from ApcMin/+;Rab25+/+ (+/+) 
and ApcMin/+;Rab25–/– (–/–) mice. Rab25-deficient mice showed an increase in tumor numbers and size throughout the intestine. (B) Anatomi-
cal distribution of polyps in small intestine (SI) of ApcMin/+;Rab25+/+ (+/+) and ApcMin/+;Rab25–/– (–/–) mice. Polyp number was determined in 
the proximal, middle, and distal intestine as well as in the total intestines of ApcMin/+;Rab25+/+ (+/+) (n = 7), ApcMin/+;Rab25+/– (+/–) (n = 16), and 
ApcMin/+;Rab25–/– (–/–) (n = 12) mice. The distal intestine showed a greater increase in the number of polyps than the proximal intestine. ApcMin/+; 
Rab25+/– mice also showed a significant increase in tumor numbers that was intermediate between wild-type and Rab25-deficient mice. Data 
represent mean ± SEM. (C) Representative Swiss rolls of proximal and distal intestine from ApcMin/+;Rab25+/+ (+/+) and ApcMin/+;Rab25–/– (–/–) 
mice. Both proximal and distal intestine from ApcMin/+;Rab25–/– (–/–) mice showed an increase in tumor number. Scale bars: 1 mm.
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polyoma middle T–expressing mice crossed onto the Rab25-null 
background and observed no significant effects of Rab25 defi-
ciency on either development of breast tumors or lung metasta-
ses (B. Fingleton and J.R. Goldenring, unpublished observations). 
In contrast, in the present study on intestinal neoplasia, Rab25 
deficiency promoted colonic neoplasia in 2 different models of 
either intestinal polyposis or invasive colon cancer. These results 
suggest that Rab25 likely influences an early step in intestinal 
neoplasia. We observed that the major expression of Rab25 in 
the intestine was in the cells just luminal to the active progenitor 
cells of the crypt. These are the same cells that are thought to be 
involved in the development of adenomas in ApcMin/+ mice (24, 31). 
It is of interest that we observed decreases in Rab25 expression in 
these cells in ApcMin/+ mice compared with wild-type mice. Further 
Figure 5
Rab25 deficiency promotes colon adenoma formation in ApcMin/+ mice. (A) 
Gross appearance of colons from ApcMin/+;Rab25+/+ (+/+) and ApcMin/+; 
Rab25–/– (–/–) mice. Rab25-deficient mice showed an increase in tumor 
number as well as an increase in tumor size throughout the colon. (B) 
The size distribution of polyps in the colons of ApcMin/+;Rab25+/+ (+/+) 
(n = 7), ApcMin/+;Rab25+/– (+/–) (n = 16), and ApcMin/+;Rab25–/– (–/–) 
mice (n = 12). ApcMin/+;Rab25–/– mice showed a significant increase in 
colon tumor numbers (**P < 0.01). Data represent mean ± SEM. (C) 
Representative Swiss rolls of colon from ApcMin/+;Rab25+/+ (+/+) and 
ApcMin/+;Rab25–/– (–/–) mice showing the prominent increase in tumor 
size in the Rab25-deficient mice. Scale bars: 1 mm.
Figure 6
Immunolocalization of Rab25. (A–H) Rab25 expression in the intestinal mucosa of ApcMin/+;Rab25+/+ (+/+) and ApcMin/+;Rab25–/– (–/–) mice. (A) ApcMin/+ 
mice with Rab25+/+ background showed decreased Rab25 immunostaining in the cells at the transition from crypt to villus. (B) No Rab25 staining was 
observed in early adenomas polyp. Rab25-positive cells were still located in the transition zone from crypt to villus in adjacent normal villi. (C) In some 
nonadenomatous areas, ectopic expression of Rab25 was observed in villus cells adjacent to developed intestinal polyps. P, polyp. (D) No Rab25 
staining was found in ApcMin/+ mice on a Rab25-deficient background. (E–H) Higher magnification views of A–D. Scale bars: 50 μm.
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reduction in Rab25 may therefore have led to the acceleration of 
adenoma formation. This concept is supported by the intermedi-
ate effect on ApcMin/+ mouse tumor formation on the haploinsuf-
ficient Rab25+/– background. While it is not clear what range of 
cargoes is affected by the loss of Rab25, we did observe prominent 
reductions in lateral β1 integrin in ApcMin/+ mice and Rab25-null 
mice. Jones et al. (31) have previously demonstrated that loss of 
β1 integrin can lead to intestinal hyperplasia. Chaurasia et al. (32) 
have also demonstrated that alterations in α5β1 integrin interac-
tions can lead to increases in metastatic behavior. Thus, loss of 
Rab25 may promote mislocalization of integrin away from the 
lateral membranes, thus promoting further proneoplastic influ-
ences. Given the variety of specific cargoes expressed in different 
epithelial cells and the previous results in breast cancer cells, it 
seems likely that either Rab25 loss or Rab25 overexpression could 
lead to transformation, depending on the particular cargoes traf-
ficked in individual epithelial cell populations.
The data presented here also support a role for Rab25 as an early 
general colonic tumor suppressor. Rab25 loss also led to a marked 
acceleration in invasive colon tumor formation in Smad3+/– mice. 
The general phenotype of the Smad3+/–;Rab25–/– mice was similar 
to previously reported accelerated pathology in ApcMin/+;Smad3–/– 
mice (33). The ApcMin/+;Smad3–/– mice also showed more rapid and 
extensive colon tumor formation. Those investigations suggested 
that Wnt and TGF-β receptor–mediated pathways could cooper-
ate in regulation of tumor suppression. In the case of the studies 
reported here, we observed marked tumor formation in Smad3 
heterozygote mice on the Rab25-deficient background. These 
results indicate that multiple pathways can synergize to lead to the 
eventual manifestation of colon tumor formation. It seems logical 
that disruption of aspects of polarized trafficking through the loss 
of Rab25 could predispose mucosal epithelial cells to secondary 
perturbations by either loss of Apc function or loss of Smad3, lead-
ing to accelerated transformation.
In summary, the present investigations demonstrate that 
loss of Rab25 leads to increased tumorigenesis in both ApcMin/+ 
mice and Smad3+/– mice. Given our findings that lower Rab25 
expression is associated with poorer prognosis in colon cancer 
patients, the present investigations suggest that reduction of 
Rab25 expression is associated with the initiation of colonic neo-
plasia. The loss of β1 integrin staining at the lateral membrane 
supports a scenario in which loss of Rab25 leads to an alteration 
in trafficking of key cargoes regulating aspects of polarity, thus 
predisposing intestinal and colonic epithelial to transformation. 
All of these findings support a role for Rab25 as an early tumor 
suppressor in the intestinal mucosa.
Methods
Construction of Rab25-deficient mice. A 20-kb fragment of the mouse Rab25 
gene containing all 5 exons was previously isolated. An EcoRV fragment 
Figure 7
β1 integrin expression in the intestinal mucosa of wild-type, Rab25–/–, ApcMin/+;Rab25+/+ (+/+), and ApcMin/+;Rab25–/– (–/–) mice. Arrows in A–D 
indicate the positions of regions shown at higher magnification. (A) Wild-type mice showed prominent lateral membrane localization of β1 inte-
grin in villus cells (arrowhead). Scale bars: 25 μm. (B) Villus cells in Rab25-deficient mice had diminished lateral staining with more prominent 
intracellular staining for β1 integrin (arrow). Scale bars: 25 μm. (C) In ApcMin/+ mice, we noted reduced β1 integrin staining in the lateral membranes 
of villus cells (arrow). Scale bars: 25 μm. (D) In ApcMin/+;Rab25–/– mice, we observed essentially complete loss of lateral β1 integrin staining, with 
staining only detected intracellularly (arrow). Scale bars: 25 μm. (E) All adenomatous polyps in ApcMin/+;Rab25+/– and ApcMin/+;Rab25–/– mice 
showed a similar marked loss of β1 integrin staining. Scale bar: 50 μm. (F) Higher magnification view of E. Scale bar: 50 μm.
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containing all 5 exons was cloned into pBluescript. The Rab25 gene was 
interrupted by insertion of the Neomycin resistance gene along with 3 tan-
dem in-frame stop codons into the second exon. The resulting transgene 
was then linearized and injected into R1 ES cells. Cells were screened for 
neomycin resistance, and candidate cell lines were examined for homolo-
gous recombination by Southern blotting of EcoRV digests of genomic 
DNA. Two selected cell lines were injected in blastocysts, and chimeras 
were identified. One founder line was transmitted 100% to offspring. The 
founders were crossed through 12 generations to both C57BL/6 mice and 
129/J mice. During the experiments, the mice were maintained with regu-
lar mouse chow and water ad libitum in a temperature-controlled room 
under a 12-hour light/12-hour dark cycle. The care, maintenance, and 
treatment of animals in these studies followed protocols approved by the 
Institutional Animal Care and Use Committee of Vanderbilt University.
Southern blotting. Genomic DNA was isolated from mouse tails using a 
QIAGEN Genomic DNA isolation kit (QIAGEN). 2 μg of genomic DNA 
was digested overnight at 37°C with EcoRV. Southern blots were probed 
with [32P]-labeled DNA probe corresponding to the unique 3′ coding 
sequence of murine Rab25.
PCR assay. 1 μg of genomic DNA was utilized to amplify wild-type and 
knockout sequences using a 3-primer reaction. Primer sequences are listed 
in Supplemental Table 3.
Anti-Rab25 antibody. The rabbit polyclonal antibody was raised against 
a specific peptide sequence at the murine Rab25 carboxyterminal vari-
able domain, QNSTRTSAITLGNAQAGQDPGLGEKR. KLH was cova-
lently attached to the N terminus for immunization of the rabbits 
(Covance). The antiserum was affinity purified against the immuni-
zation peptide covalently coupled by the carboxyl terminus to a solid 
matrix (EDC/Diaminodipropylamine Immobilization kit; Pierce). Rab25 
antibodies did not recognize either recombinant Rab11a or Rab11b 
(L. Lapierre and J.R. Goldenring, unpublished observations). Rab25 
antibodies stained discrete populations of epithelial cells, including 
stomach, esophagus, skin, tongue, and kidney (Supplemental Figure 1) 
as well as cells within the intestines.
Table 1
Colon tumor development in Smad3+/– mice in the absence of Rab25
Genotype	 Tumor-bearing		 Average		 Adenoma		 	 Depth	of	tumor	invasion	 	 Rectal	
	 mice	 tumor	no.	 no.	 Submucosa	 Muscularis	 Serosa	 tumor
Smad3+/–;Rab25+/+ 0/10 0 0 0 0 0 0
Smad3+/–;Rab25–/–	 8/10 5.75 ± 1.13 1.34 ± 0.2 2.86 ± 0.59 2.8 ± 0.29 1.25 ± 0.17 1.0 ± 0.0
Quantitation of tumor development in Smad3+/– mice. For tumor-bearing mice, the average numbers of tumors per colon and adenomas per colon were 
determined (± SEM). In addition, we assessed the number of tumors per mouse that invaded the submucosa, muscularis mucosa, or the serosa. Finally, 
we assessed the number of rectal tumors present per mouse. No tumors were observed in Smad3+/– mice on a wild-type Rab25 background.
Figure 8
Rab25 deficiency promotes colon tumor formation and neoplasia in Smad3+/– mice. (A) Smad3 heterozygote mice on a Rab25 wild-type 
background did not show any adenomas in their colons. (B) Higher magnification of view of A shows normal colonic mucosa. (C) Swiss roll 
of Smad3+/–;Rab25–/– mouse colon. Note the numerous mucin-filled cysts. The image was captured using an Ario SL-50 imager. Areas of the 
image in which no tissue was present appear blank. (D) In a more aggressive proximal tumor, the cancerous lesions penetrated into the serosal 
wall with neoplastic atypical cystic glands filled with mucin. (E) The neoplastic colonic epithelium invaded into and through the submucosa, and 
the neoplastic glands invaded the muscle wall. (F) Rectal area of Smad3+/–;Rab25–/– mice. The neoplastic colonic epithelium penetrated muscle 
wall with atypical cystic glands filled with mucin. (G) Atypical cystic glands in epithelium and penetrating the muscle wall. (H) Vagina neoplasia. 
In vaginal epithelium, neoplastic squamous epithelial cells invaded the muscle layer. The vaginal lesions were not specific to ApcMin/+ mice and 
were seen in Rab25-deficient mice on the 129 background. Scale bars: 1 mm.
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Generation of ApcMin/+ Rab25–/–, ApcMin/+;Rab25+/–, and ApcMin/+;Rab25+/+. 
C57BL/6J-ApcMin/+ mice were obtained from The Jackson Laboratory. 
ApcMin/+ males were mated with C57BL/6 background Rab25–/– females to 
generate ApcMin/+;Rab25+/– mice. Such males were backcrossed with Rab25–/– 
mice to generate ApcMin/+;Rab25–/– animals. To generate ApcMin/+;Rab25+/+, 
male ApcMin/+ mice were mated with wild-type female mice. The genotype of 
the offspring for ApcMin/+ was analyzed by a PCR assay method (Supplemen-
tal Table 3). All of the mice were killed at the age of 15 weeks.
Generation of Smad3+/–;Rab25–/– and Smad3+/–;Rab25+/+. We used 129/J-
Smad3+/– mice. Smad3+/– males were mated with 129/J background Rab25–/– 
females to generate Smad3+/–;Rab25+/– mice. Such males were backcrossed 
with Rab25–/– mice to generate Smad3+/–;Rab25–/– animals. The genotype of 
the offspring for Smad3+/– was analyzed by a PCR assay method (Supple-
mental Table 3). All of the mice were killed at the age of 10 months.
Polyp number scoring and histopathology. Immediately after sacrifice, both 
ends of the small and large intestines were tied with thread, and the guts 
were inflated with 10% phosphate-buffered formalin. After 24 hours, they 
were opened longitudinally to wash the formalin and luminal contents from 
the mucosal surface. The numbers and the major diameters of the polyps in 
small and large bowels were measured per ×10 power field of a stereoscopic 
microscope. For histological examination, formalin-fixed intestines were 
prepared by the Swiss roll method and embedded in paraffin, and 5-μm 
sections were prepared for H&E staining and immunohistochemistry.
Analysis of human-expression profiling. Gene expression data from Kaiser 
et al. (21) was analyzed using Robust MultiChip Averaging (RMA) nor-
malized values from a series of 100 carefully dissected colorectal cancer 
isolates that were compared with 5 normal colonic mucosal samples. These 
samples were collected with informed subject consent and analyzed under 
a protocol approved by the Institutional Review Board of the Moffitt Can-
cer Center. Probe sets and corresponding gene transcripts whose expres-
sion was highly correlated to that of RAB25 were identified in the human 
data set using Pearson correlation to the high-quality probe set for human 
RAB25, 218186_at, as measured versus all probe sets with gene expression 
greater than an RMA of 6.0 in more than 4 samples. This generated a list of 
530 correlated probe sets. Enrichment analysis for overrepresented gene-
associated features including known protein interactions, pathways, and 
shared gene ontology relationships was performed using ToppGene (34).
The protocols and procedures for the Vanderbilt Medical Center (VMC) 
cohort were approved by the Institutional Review Boards at the Univer-
sity of Alabama-Birmingham Medical Center (Birmingham, AL, USA), 
Vanderbilt Medical Center, and the Veterans Administration Hospital 
(Nashville, TN). Representative sections of fresh tissue specimens were 
flash frozen in liquid nitrogen and stored at –80°C until RNA isolation. 
Quality assessment slides were obtained to verify the diagnosis. Stage was 
assessed by American Joint Commission on Cancer (AJCC) guidelines for 
the tumor samples. RNA was purified using the RNeasy kit (QIAGEN). 
Human samples were hybridized to the Human Genome U133 Plus 2.0 
GeneChip Expression Affymetrix array. Microarray data were normalized 
using the RMA algorithm (35) as implemented in the Bioconductor pack-
age Affy. For pairwise group comparisons, t test in the Limma package (36) 
in Bioconductor was used to identify differentially expressed probe sets 
between the 2 groups under comparison. The implementation of t test in 
Limma uses an empirical Bayes method to moderate the standard errors 
of the estimated log fold changes; this results in a more stable inference, 
especially for experiments with a small number of arrays.
RNA collection for quantitative RT-PCR. Four normal colon samples were 
taken from patients with diverticulitis, and 10 colon adenocarcinoma 
samples were obtained at VMC. The patient samples used for this analysis 
were independent of the 61 samples used for the adenoma-to-carcinoma 
comparison. All adenocarcinoma patients for the qPCR work were staged 
by AJCC criteria. All protocols and procedures were approved by the Van-
derbilt Institutional Review Board. Criteria for use of normal or tumor 
samples was greater than 80% contribution of normal mucosa or tumor on 
the H&E slides used to determine potential for RNA isolation. Once nor-
mal mucosa or tumor was verified, RNA was collected from fresh frozen 
tissue with the QIAGEN RNeasy kit. Samples were DNAse treated on col-
umn (QIAGEN) during purification and eluted with 50 μl RNAse/DNAse-
free water. RNA integrity was determined on an Agilent Bioanalyzer (Agi-
lent Technologies Inc.). Samples with RNA integrity numbers suitable for 
hybridization for microarray analysis (RNA integrity > 6.2) were used.
Quantitative RT-PCR. RNA (300 ng) was reverse transcribed using oligo-
dT primers and SuperScript III (Invitrogen) reverse transcriptase. 20 μl 
reactions were incubated for 30 minutes at 50°C followed by 5 minutes at 
95°C to inactivate enzyme. All cDNAs were diluted with 80 μl of nuclease-
free water. PCR reactions were performed using gene-specific primers for 
Rab25 and PMM1 as a control (PMM1 sense: 5′-CTCCTAGTGGCACT-
GGCTTC-3′ and PMM1 antisense: 5′-GCAGGCTAGATCTCGTACCG-3′; 
Rab25 sense: 5′-TCGCTGAAAACAATGGACTGCTCTT-3′ and Rab25 
antisense: 5′- ATTGGTCCGGATGCTGTTCTGTCTCT-3′). Each well con-
tained SYBR Green Master Mix from SuperArray combined with primer 
sets (10 μM) and 1 μl of cDNA prepared and used on the same day for 
the PCR reactions. Each cDNA reaction was loaded in quadruplicate in 
96-well plates and run on a Bio-Rad iCycler under the following protocol 
(1: 95°C, 30 seconds; 2: 95°C, 30 seconds; 3: 95°C, 13 minutes–30 sec-
onds; 4: 95°C, 15 seconds; 55°C, 30 seconds; 72°C, 30 seconds (45 cycles); 
5: 72°C, 7 minutes; 6: 55°C, 10 minutes).
For each individual well, fluorescence curves were log transformed, and 
the slope of the logarithmic portion of the reaction was extracted to deter-
mine efficiency. Ct values and efficiency were then utilized to calculate fold 
change (37). Normalization was done with PMM1 (38). Efficiency-adjusted 
Ct values were determined for normal and tumor samples. Ct values for each 
normal and for each tumor sample were determined compared with a nor-
mal or tumor reference Ct value, and 1/Ct was then displayed. Significant 
differences were determined using a nonparametric Mann-Whitney U test.
Immunohistochemistry. We carried out immunohistochemistry according 
to the manufacturer’s recommendations, typically using a modified citric 
acid unmasking protocol followed by standard detection with 3,3′-diami-
nobenzidine (DAB) using a kit from Vector Laboratories. Samples were 
counter-stained with hematoxylin. In some cases, secondary antibodies 
were conjugated to Alexa Fluor 488 (Invitrogen), and nuclei were coun-
terstained with DAPI. We used the following primary antibodies: rabbit 
anti-rab25 (1:20) and rat anti–β1 integrin (1:100; Chemicon).
Loss of heterozygosity analysis and laser capture microdissection. In the current 
study, the DNA for the analysis of the Apc allelic loss was extracted from 
the cells isolated with laser microdissected tissue sections as described 
previously (26). Microdissection was done using a laser microdissection 
system (Molecular Devices). The microdissected tissues of tumors from 
ApcMin/+;Rab25+/+ and ApcMin/+;Rab25–/– mice were used for the analysis. 
Genomic DNA was extracted and isolated using PicoPure DNA Isolation 
Kit (Molecular Devices) immediately following collection of tissues. Loss 
of heterozygosity (LOH) of the Apc gene was assessed using PCR with mis-
matched primers as described previously (25).
Statistics. The data were analyzed with the JMP software package (version 
4.0; SAS Institute). Polyp numbers were compared with analysis of variance 
followed by post hoc analysis of significant means by Dunnett’s test. For all 
comparisons, P values less than 0.05 were considered statistically significant.
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